BioXcel Therapeutics BTAI Cash Flow Statement (2017-2026)

NASDAQ BTAI
$0.04 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT
Reported Financials

BioXcel Therapeutics Quarterly Cash Flow Statement

Periods 38 quarters
Latest Jun 2026

BioXcel Therapeutics reported cash from operations of -$6.10M and free cash flow of -$6.10M for the quarter ended Jun 2026, up 51.5% year over year. This cash flow statement covers 38 quarters of results from Mar 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-26.82M-26.09M-31.47M-37.67M-41.87M-54.33M-52.55M-54.05M-50.48M-22.36M-26.82M-20.32M-18.47M-14.16M-13.81M-19.84M-18.36M-14.36M-14.21M-14.32M
Share-based Compensation
4.89M2.24M4.68M4.48M4.48M4.55M5.64M6.12M5.50M3.60M4.85M4.83M5.23M-0.20M0.37M1.56M0.58M0.45M0.51M0.47M
Cash from Operations
-20.20M-19.93M-32.41M-33.10M-31.19M-38.64M-52.35M-38.21M-37.58M-26.86M-17.71M-23.17M-16.34M-14.81M-12.04M-12.57M-18.79M-14.21M-11.81M-6.10M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.07M0.07M0.07M0.07M0.07M0.07M0.08M0.08M0.08M0.08M0.08M0.08M0.06M
Amortization of Deferred Charges
0.32M0.22M0.32M0.33M0.36M0.38M0.31M0.04M0.10M0.11M0.22M0.35M0.39M0.44M0.47M0.50M0.77M
Depreciation & Amortization (CF)Depreciation & Amortization
0.08M0.08M0.08M
Change in Working Capital
Change in Receivables
0.04M0.15M0.30M-0.66M0.31M0.43M-0.81M0.13M-0.13M0.02M-0.02M0.23M-0.02M-0.13M
Change in Inventory
0.68M0.71M0.01M0.58M-0.03M-0.03M0.09M-0.03M0.45M0.24M-1.16M-0.85M-0.04M-0.14M-0.05M0.26M-0.22M-0.02M
Change in Account Payables
Change in Accured Expenses
2.25M2.04M-0.68M3.99M0.48M9.23M-4.65M6.89M6.86M-12.32M4.83M-4.16M-1.66M-3.33M-2.27M2.31M-1.08M8.01M2.21M1.83M
Other Working Capital Changes
0.68M-1.98M3.48M3.59M-2.14M-1.03M2.01M-1.48M-2.25M-1.16M-0.90M0.46M1.46M0.85M-0.61M-0.07M0.39M8.44M1.04M-1.68M
Investing Activities
Capital Expenditures
0.02M0.01M0.12M0.02M
Cash from Investing Activities
-0.02M-0.01M-0.12M-0.02M
Financing Activities
Other financing activities
0.10M3.25M3.06M0.26M0.25M0.22M2.32M6.17M1.42M
Debt Issuance and Repayment
Long-Term Debt Issuances
30.00M
Long-Term Debt Repayments
8.11M0.30M
Change in Capital Stock
Net Shares Issued and Repurchased
0.87M0.84M1.38M0.96M1.09M0.02M0.04M0.07M0.08M0.12M
Net Equity Issued and Repurchased
-0.03M24.66M2.38M0.47M7.00M14.01M0.14M38.23M5.76M8.50M3.11M
Misc.
Cash from Financing Activities
0.07M30.05M0.05M24.15M0.25M2.12M26.63M5.30M0.45M4.28M13.20M0.14M37.53M5.65M0.23M2.72M
Change in Cash
-20.14M-19.94M-32.53M33.02M-1.14M-38.59M-28.20M-37.98M-37.58M-24.74M8.92M-17.87M-15.88M-10.53M1.16M-12.44M18.75M-8.56M-11.58M-3.38M
Free Cash Flow
-20.22M-19.94M-32.53M-33.12M-31.19M-38.64M-52.35M-38.21M-37.58M-26.86M-17.71M-23.17M-16.34M-14.81M-12.04M-12.57M-18.79M-14.21M-11.81M-6.10M
Net Cash Flow
-20.14M-19.94M-32.53M-33.12M-1.14M-38.59M-28.20M-37.96M-37.58M-24.74M8.92M-17.87M-15.88M-10.53M1.16M-12.44M18.75M-8.56M-11.58M-3.38M